MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$2.05 +2.02%

+$0.08 today

Market cap
$131.01M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.57M

Average 0.98M

MGNX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MacroGenics, Inc.NASDAQ: MGNX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $33.29M fell 12.2% year over year, ahead of the -19.9% change in trailing-twelve-month research & development. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.

Context

  • Research & development amounted to 93.6% of revenue in FY2025, down 25.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -12.2% holds above the trailing-twelve-month pace of -19.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.29M+3.2% QoQ
Last fiscal yearDec 2025
$140M-21.0% YoY
LTMMar 2026
$135.36M-19.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.2%——
1 year-21.0%——
3-year CAGR-12.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
140M USD
Year-over-year change
-21.0%
4-year CAGR
-10.1%

Research & Development vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.9% is the 7th highest of 11, against a peer median of -13.4%.
  • Research & development amounts to 86.2% of revenue for MGNX, versus a peer median of 27954.8%.
MGNX Competitors
Research & Development for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$3.68B USD+26273.1%+50.2%46313.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$108.76M USD-25.2%-14.7%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$99.41M USD+115.1%+40.7%—
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding MGNX) —-13.4%-13.3%27954.8%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$2.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.